A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy — EXPAND

Childhood Absence Epilepsy Clinical Trial

Official title:
A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Status Recruiting

Clinical Trial Summary

The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04666610
Study type	Interventional
Source	UCB Pharma
Contact	UCB Cares
Phone	+1844599
Email	UCBCares@ucb.com
Status	Recruiting
Phase	Phase 3
Start date	July 29, 2021
Completion date	February 25, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00393666` - Why Are Patients With Absence Seizures Absent? A Brain Imaging Study	N/A
Terminated	`NCT06153186` - Flunarizine for Treatment Resistant Absence Epilepsy	Phase 2
Enrolling by invitation	`NCT05109234` - A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy	Phase 3
Not yet recruiting	`NCT06315322` - A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy	Phase 3
Completed	`NCT00088452` - Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study	Phase 3
Terminated	`NCT03355300` - Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures	Phase 2
Terminated	`NCT03336242` - Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures	Phase 2
Completed	`NCT00361010` - A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy	N/A
Completed	`NCT00041951` - Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study	N/A
Recruiting	`NCT06310772` - Assessing Comorbidities in Epilepsy Using Eye Movement Recordings